One of the main goals of NewDrug is the R&D of anti-hypertensive products, targeting the RAS (Renin-Angiotensin System). The main strategic objective is the development of “advanced” substances through the evolution of other substances as well as implementation research to identify new potential drug candidates. NewDrug is also involved in the development of new formulations. R&D is the result of pioneer work led by Professors John Matsoukas and Graham Moore.
Hypertension Research Network
- Department of Chemistry, University of Patras, Greece
- Department of Medicine, University of Patras, Greece
- National Hellenic Research Foundation (NHRF) Athens, Greece
- Health Science Center, University of Calgary, Alberta, Canada
- Department of Pharmacology, Medical School, University of Crete, Greece
- Department of Chemistry, University of Athens, Greece
- Institute of Organic Chemistry and Biochemistry, Charles University of Prague, The Czech Republic
- Department of Internal Medicine, “Attikon” University Hospital, Athens, Greece
- College of Health and Biomedicine, Victoria University, Australia